Goljanian Tabrizi Ali, Safavi Naini Abbas, Baradaran Nima
Department of Otolaryngology, Shaheed Beheshti University of Medical Sciences, Tehran, Iran.
Iran J Otorhinolaryngol. 2017 Mar;29(91):95-100.
Although several treatment approaches have been proposed for tinnitus, there are currently no Food and Drug Administration (FDA)-approved agents available to treat this condition. In this study, we evaluated the effect of gabapentin on the sensation of subjective tinnitus in patients with acoustic trauma referring to the ear, nose and throat (ENT) clinic of Taleghani Hospital during 2014.
In this double-blind, randomized clinical trial, 103 patients with tinnitus due to acoustic trauma who were referred to the ENT clinic of Taleghani Hospital during 2014 were randomized to the gabapentin (300 mg bid, n=55) or control (n=48) groups. The two groups were then compared before and after 6 weeks of treatment using a visual analog scale (VAS). At least a 30% reduction in VAS was considered a response to treatment.
Differences between the two groups regarding sex, age, duration of disease, and audiometry results was not significant (P>0.05). After 6 weeks' treatment, the VAS significantly decreased in both groups (P<0.001), but the reduction was significantly greater in the gabapentin group compared with control (P<0.001). Forty-nine patients (89%) in the gabapentin group and 28 control patients (58.3%) responded to treatment (≥30% reduction in VAS), with the difference between the two groups being statistically significant (P<0.001).
We conclude that gabapentin 300 mg bid for 6 weeks is an effective treatment for acoustic tinnitus. In addition, the placebo effect in relieving tinnitus is remarkable.
尽管针对耳鸣已经提出了几种治疗方法,但目前尚无美国食品药品监督管理局(FDA)批准的用于治疗该病症的药物。在本研究中,我们评估了加巴喷丁对2014年转诊至塔莱加尼医院耳鼻喉科门诊的声创伤患者主观耳鸣感觉的影响。
在这项双盲、随机临床试验中,2014年转诊至塔莱加尼医院耳鼻喉科门诊的103例因声创伤导致耳鸣的患者被随机分为加巴喷丁组(300毫克,每日两次,n = 55)或对照组(n = 48)。然后使用视觉模拟量表(VAS)在治疗6周前后对两组进行比较。VAS至少降低30%被视为对治疗有反应。
两组在性别、年龄、病程和听力测试结果方面的差异无统计学意义(P>0.05)。治疗6周后,两组的VAS均显著降低(P<0.001),但加巴喷丁组的降低幅度明显大于对照组(P<0.001)。加巴喷丁组49例患者(89%)对治疗有反应(VAS降低≥30%),对照组28例患者(58.3%)有反应,两组之间的差异具有统计学意义(P<0.001)。
我们得出结论,6周内每日两次服用300毫克加巴喷丁是治疗声源性耳鸣的有效方法。此外,安慰剂在缓解耳鸣方面的效果显著。